Sonic Healthcare Limited (DE:SAB0)
FRANKFURT:SAB0
SAB0 Stock Chart & Stats
€12.60
€0.00(0.00%)
At close: 4:00 PM EST
€12.60
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€10.90 - €15.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.77B
Enterprise Value€16.99B
Total Cash (Recent Filing)€556.57M
Total Debt (Recent Filing)€7.34B
Price to Earnings (P/E)17.7
Beta0.19
Next Earnings
Aug 20, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding494,237,950
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.57
Price to Sales (P/S)1.35
P/FCF Ratio13.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.74
Revenue Forecast (FY)€6.71B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowSonic's outsized free cash flow growth and high cash conversion provide durable financial flexibility. Strong FCF supports maintenance capex, progressive dividends, selective M&A and potential buybacks while reducing reliance on new debt, underpinning capital allocation over 2–6 months.
Consistent Revenue & Organic GrowthSustained organic growth across markets (Australia, Germany, UK, radiology) reflects recurring diagnostic demand and diversified revenue streams. Durable underlying volume growth reduces reliance on one-off items and supports predictable revenue base and margin recovery over the medium term.
Acquisition Integration & Platform ScaleProgressing integration of acquisitions and roll‑out of digital pathology and advanced diagnostics creates scalable service mix and potential synergies. Platform scale, tech-enabled workflows and cross-market synergies can drive sustainable margin expansion and higher specialised-test revenue mix.
Bears Say
U.S. Margin Pressure & RestructuringPersistent low organic growth, restructuring charges and delayed collection benefits in the U.S. create a structural near-term earnings drag. Given the market's scale, slower recovery or integration risk can weigh on group margins and EBITDA durability for multiple quarters.
Elevated Net Debt & Working CapitalBilling disruptions and acquisition-related capex increased receivables and net debt, reducing financial headroom. Higher short-term leverage constrains capital allocation flexibility and raises refinancing or covenant risk, limiting ability to fund growth or absorb shocks over the medium term.
Reimbursement, Wage & FX UncertaintyRegulatory fee reform, wage rulings and currency swings create structural margin volatility across key markets. Uncertain reimbursement and higher labour costs can compress margins persistently, while FX variability affects reported EBITDA and planning visibility over several quarters.
Sonic Healthcare News
SAB0 FAQ
What was Sonic Healthcare Limited’s price range in the past 12 months?
Sonic Healthcare Limited lowest stock price was €10.90 and its highest was €15.80 in the past 12 months.
What is Sonic Healthcare Limited’s market cap?
Sonic Healthcare Limited’s market cap is €5.77B.
When is Sonic Healthcare Limited’s upcoming earnings report date?
Sonic Healthcare Limited’s upcoming earnings report date is Aug 20, 2026 which is in 74 days.
How were Sonic Healthcare Limited’s earnings last quarter?
Sonic Healthcare Limited released its earnings results on Feb 18, 2026. The company reported €0.303 earnings per share for the quarter, missing the consensus estimate of €0.307 by -€0.003.
Is Sonic Healthcare Limited overvalued?
According to Wall Street analysts Sonic Healthcare Limited’s price is currently Overvalued.
Does Sonic Healthcare Limited pay dividends?
Sonic Healthcare Limited does not currently pay dividends.
What is Sonic Healthcare Limited’s EPS estimate?
Sonic Healthcare Limited’s EPS estimate is 0.4.
How many shares outstanding does Sonic Healthcare Limited have?
Sonic Healthcare Limited has 494,237,950 shares outstanding.
What happened to Sonic Healthcare Limited’s price movement after its last earnings report?
Sonic Healthcare Limited reported an EPS of €0.303 in its last earnings report, missing expectations of €0.307. Following the earnings report the stock price went up 6.202%.
Which hedge fund is a major shareholder of Sonic Healthcare Limited?
Currently, no hedge funds are holding shares in DE:SAB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sonic Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.10%
12-Months-Change
Fundamentals
Return on Equity
6.39%
Trailing 12-Months
Asset Growth
19.27%
Trailing 12-Months
Company Description
Sonic Healthcare Limited
Sonic Healthcare Limited offers medical diagnostic services in Australia. The company provides laboratory medicine/pathology; diagnostic imaging/radiology, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry; and primary care medical services comprising general practice services, occupational health services, remote health services, community and home nursing services, primary care research programs, health assessment technologies, clinical trials, and chronic disease management programs to clinicians, hospitals, community health services, and their patients. It also offers administrative services and facilities to medical practitioners. The company operates in Australia, New Zealand, the United Kingdom, the United States, Germany, Switzerland, Belgium, and Ireland. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
SAB0 Company Deck
SAB0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presents a largely positive operational and financial picture: strong H1 results (revenue, EBITDA, net profit), maintained full-year EBITDA guidance, margin improvement at group level (+30 bps), successful integration progress in major acquisitions (Germany LADR and Swiss deals), and continued organic growth across several markets (Australia, Germany, UK, Radiology). Offsetting these positives are concentrated challenges in the U.S. (margin pressure, restructuring and delayed revenue collection benefits), elevated short-term net debt and working capital due to acquisitions and the Change Healthcare billing disruption, FX headwinds for H2, and some regulatory/wage uncertainties (Germany GOA reform and Australian Fair Work outcomes). Management has clear remediation and capital management plans (operating review, sale-and-leaseback program, potential buybacks) and has retained guidance, supporting a constructive outlook despite identifiable near-term risks.View all DE:SAB0 earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---